Geode Capital Management’s Burning Rock Biotech BNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,560
Closed -$18.7K 4587
2024
Q1
$18.7K Hold
2,560
﹤0.01% 4490
2023
Q4
$23.8K Hold
2,560
﹤0.01% 4484
2023
Q3
$24.8K Hold
2,560
﹤0.01% 4582
2023
Q2
$55.8K Hold
2,560
﹤0.01% 4482
2023
Q1
$71.9K Buy
2,560
+731
+40% +$21.9K ﹤0.01% 4436
2022
Q4
$41K Sell
1,829
-876
-32% -$20K ﹤0.01% 4641
2022
Q3
$64K Hold
2,705
﹤0.01% 4706
2022
Q2
$78K Sell
2,705
-3,678
-58% -$164K ﹤0.01% 4670
2022
Q1
$592K Sell
6,383
-40
-0.6% -$3.48K ﹤0.01% 3858
2021
Q4
$612K Sell
6,423
-11,119
-63% -$1.52M ﹤0.01% 3938
2021
Q3
$3.11M Buy
17,542
+973
+6% +$216K ﹤0.01% 3172
2021
Q2
$4.84M Buy
16,569
+14,291
+627% +$4.23M ﹤0.01% 2929
2021
Q1
$613K Buy
+2,278
New +$693K ﹤0.01% 3734
2020
Q3
Sell
-742
Closed -$200K 4159
2020
Q2
$200K Buy
+742
New +$203K ﹤0.01% 3665

Other funds holding BNR

Geode Capital Management's BNR Position: Q2 2024 in Review

Geode Capital Management sold out of Burning Rock Biotech (BNR) in Q2 2024, closing a stake of 2,560 shares — an estimated $18.7K sold.

Geode Capital Management first reported a position in BNR in Q2 2020 and held it in 14 quarters. The position peaked at $4.84M in Q2 2021. 18 funds tracked by Wall St. Rank hold BNR as of Q2 2024.

  • Geode Capital Management reported no remaining Burning Rock Biotech position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 2,560 Burning Rock Biotech shares in Q2 2024, an estimated $18.7K.
  • Geode Capital Management first reported a position in Burning Rock Biotech in Q2 2020 and held it in 14 quarters.
  • Geode Capital Management's Burning Rock Biotech position peaked at $4.84M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.